Irritable bowel syndrome: An integrated explanatory model for clinical practice

Neurogastroenterology and Motility

Volumn 27, Issue 6, 2015, Pages 750-763

  Hungin, A Pali S ^a   Becher, A ^a,b   Cayley, B ^c   Heidelbaugh, J J ^d   Muris, J W M ^e   Rubin, G ^a   Seifert, B ^f   Russell, A ^g   De Wit, N J ^h  

^a DURHAM UNIVERSITY   (United Kingdom)

^b OXFORD PHARMAGENESIS LTD   (United Kingdom)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f CHARLES UNIVERSITY   (Czech Republic)

^g DURHAM UNIVERSITY   (United Kingdom)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Explanations; Explanatory models; Irritable bowel syndrome; Mechanisms

Indexed keywords

SEROTONIN; SEROTONIN 3 RECEPTOR;

CLINICAL PRACTICE; DEFECATION HABIT; DISTRESS SYNDROME; EPIGENETICS; GENERAL PRACTITIONER; GENETIC POLYMORPHISM; HEALTH CARE MANAGEMENT; HUMAN; HYPERSENSITIVITY; INTESTINE FUNCTION; IRRITABLE COLON; NONHUMAN; ONSET AGE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSOMATIC DISORDER; QUALITY OF LIFE; REVIEW; VISCERAL HYPERSENSITIVITY; COMPLICATION; DYSBIOSIS; GASTROINTESTINAL TRACT; GENETIC PREDISPOSITION; INNERVATION; INTESTINE FLORA; IRRITABLE BOWEL SYNDROME; MENTAL STRESS; PATHOPHYSIOLOGY; PATIENT EDUCATION; PSYCHOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION; SOMATOSENSORY DISORDER; SYNAPTIC TRANSMISSION;

DYSBIOSIS; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRRITABLE BOWEL SYNDROME; PATIENT EDUCATION AS TOPIC; POLYMORPHISM, GENETIC; SIGNAL TRANSDUCTION; SOMATOSENSORY DISORDERS; STRESS, PSYCHOLOGICAL; SYNAPTIC TRANSMISSION;

EID: 84929655256     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12524     Document Type: Review

References (130)

1. Spiegel BM, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 2010; 105: 848-58.
2. Casiday RE, Hungin AP, Cornford CS, de Wit NJ, Blell MT. GPs' explanatory models for irritable bowel syndrome: a mismatch with patient models? Fam Pract 2009; 26: 34-9.
3. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
4. McCormick JB, Hammer RR, Farrell RM, Geller G, James KM, Loftus EV Jr, Mercer MB, Tilburt JC et al. Experiences of patients with chronic gastrointestinal conditions: in their own words. Health Qual Life Outcomes 2012; 10: 25.
5. Casiday RE, Hungin AP, Cornford CS, de Wit NJ, Blell MT. Patients' explanatory models for irritable bowel syndrome: symptoms and treatment more important than explaining aetiology. Fam Pract 2009; 26: 40-7.
6. Sperber AD, Drossman DA, Quigley EM. The global perspective on irritable bowel syndrome: a Rome Foundation-World Gastroenterology Organisation symposium. Am J Gastroenterol 2012; 107: 1602-9.
7. Kleinman A, Eisenberg L, Good B. Culture, illness, and care: clinical lessons from anthropologic and cross-cultural research. Ann Intern Med 1978; 88: 251-8.
8. Centre for Reviews and Dissemination. Systematic Review: CRD's Guidance for Undertaking Reviews in Health Care. York: CRD, University of York, 2009.
9. Kleinman A. Patients and Healers in the Context of Culture. An Exploration of the Borderland Between Anthropology, Medicine, and Psychiatry. Berkeley, Los Angeles, and London: University of California Press, 1980.
10. Kleinman A. From illness as culture to caregiving as moral experience. N Engl J Med 2013; 368: 1376-7.
11. Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977; 196: 129-36.
12. Drossman DA. Presidential address: gastrointestinal illness and the biopsychosocial model. Psychosom Med 1998; 60: 258-67.
13. Su AM, Shih W, Presson AP, Chang L. Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern. Neurogastroenterol Motil 2014; 26: 36-45.
14. Dinan TG, Cryan J, Shanahan F, Keeling PW, Quigley EM. IBS: an epigenetic perspective. Nat Rev Gastroenterol Hepatol 2010; 7: 465-71.
15. Saito YA. Genes and irritable bowel syndrome: is there a link? Curr Gastroenterol Rep 2008; 10: 355-62.
16. van Tilburg MA, Whitehead WE. New paradigm for studying genetic contributions to irritable bowel syndrome. Dig Dis Sci 2012; 57: 2484-6.
17. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012; 367: 1626-35.
18. Mawe GM, Coates MD, Moses PL. Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 1067-76.
19. Collins SM, Denou E, Verdu EF, Bercik P. The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liver Dis 2009; 41: 850-3.
20. Camilleri M, Di Lorenzo C. Brain-gut axis: from basic understanding to treatment of IBS and related disorders. J Pediatr Gastroenterol Nutr 2012; 54: 446-53.
21. Camilleri M, Talley NJ. Pathophysiology as a basis for understanding symptom complexes and therapeutic targets. Neurogastroenterol Motil 2004; 16: 135-42.
22. Camilleri M. Intestinal secretory mechanisms in irritable bowel syndrome-diarrhea. Clin Gastroenterol Hepatol 2014. doi: 10.1016/j.cgh.2014.07.020. [Epub ahead of print].
23. Camilleri M, Busciglio I, Acosta A, Shin A, Carlson P, Burton D, Ryks M, Rhoten D et al. Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea. Am J Gastroenterol 2014; 109: 1621-30.
24. Camilleri M, Carlson P, Acosta A, Busciglio I, Nair AA, Gibbons SJ, Farrugia G, Klee EW. RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study. Am J Physiol Gastrointest Liver Physiol 2014; 306: G1089-98.
25. Spiller R, Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil. 2012; 18: 258-68.
26. Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, Spiller RC. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 349-57.
27. Grasberger H, Chang L, Shih W, Presson AP, Sayuk GS, Newberry RD, Karagiannides I, Pothoulakis C et al. Identification of a functional TPH1 polymorphism associated with irritable bowel syndrome bowel habit subtypes. Am J Gastroenterol 2013; 108: 1766-74.
28. Kilpatrick LA, Labus JS, Coveleskie K, Hammer C, Rappold G, Tillisch K, Bueller JA, Suyenobu B et al. The HTR3A polymorphism c.-42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome. Gastroenterology 2011; 140: 1943-51.
29. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397-414.
30. Talley NJ. Irritable bowel syndrome. Intern Med J 2006; 36: 724-8.
31. O'Mahony S, Chua AS, Quigley EM, Clarke G, Shanahan F, Keeling PW, Dinan TG. Evidence of an enhanced central 5HT response in irritable bowel syndrome and in the rat maternal separation model. Neurogastroenterol Motil 2008; 20: 680-8.
32. Shufflebotham J, Hood S, Hendry J, Hince DA, Morris K, Nutt D, Probert C, Potokar J. Acute tryptophan depletion alters gastrointestinal and anxiety symptoms in irritable bowel syndrome. Am J Gastroenterol 2006; 101: 2582-7.
33. Kenna GA, Roder-Hanna N, Leggio L, Zywiak WH, Clifford J, Edwards S, Kenna JA, Shoaff J et al. Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy. Pharmgenomics Pers Med. 2012; 5: 19-35.
34. Arebi N, Gurmany S, Bullas D, Hobson A, Stagg A, Kamm M. Review article: the psychoneuroimmunology of irritable bowel syndrome - an exploration of interactions between psychological, neurological and immunological observations. Aliment Pharmacol Ther 2008; 28: 830-40.
35. Talley NJ. A unifying hypothesis for the functional gastrointestinal disorders: really multiple diseases or one irritable gut? Rev Gastroenterol Disord. 2006; 6: 72-8.
36. Connor BA, Riddle MS. Post-infectious sequelae of travelers' diarrhea. J Travel Med. 2013; 20: 303-12.
37. Ghoshal UC, Ranjan P. Post-infectious irritable bowel syndrome: the past, the present and the future. J Gastroenterol Hepatol 2011; 26(Suppl. 3): 94-101.
38. Crentsil V. Will corticosteroids and other anti-inflammatory agents be effective for diarrhea-predominant irritable bowel syndrome? Med Hypotheses 2005; 65: 97-102.
39. Schwetz I, Bradesi S, Mayer EA. The pathophysiology of irritable bowel syndrome. Minerva Med 2004; 95: 419-26.
40. Haller D. Intestinal epithelial cell signalling and host-derived negative regulators under chronic inflammation: to be or not to be activated determines the balance towards commensal bacteria. Neurogastroenterol Motil 2006; 18: 184-99.
41. Ringel Y, Maharshak N. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2013; 305: G529-41.
42. Keita AV, Soderholm JD. The intestinal barrier and its regulation by neuroimmune factors. Neurogastroenterol Motil 2010; 22: 718-33.
43. Rijnierse A, Nijkamp FP, Kraneveld AD. Mast cells and nerves tickle in the tummy: implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol Ther 2007; 116: 207-35.
44. Martinez C, Gonzalez-Castro A, Vicario M, Santos J. Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome. Gut Liv 2012; 6: 305-15.
45. Bashashati M, Rezaei N, Andrews CN, Chen CQ, Daryani NE, Sharkey KA, Storr MA. Cytokines and irritable bowel syndrome: where do we stand? Cytokine 2012; 57: 201-9.
46. Esmaili A, Nazir SF, Borthakur A, Yu D, Turner JR, Saksena S, Singla A, Hecht GA et al. Enteropathogenic Escherichia coli infection inhibits intestinal serotonin transporter function and expression. Gastroenterology 2009; 137: 2074-83.
47. Ilnyckyj A, Balachandra B, Elliott L, Choudhri S, Duerksen DR. Post-traveler's diarrhea irritable bowel syndrome: a prospective study. Am J Gastroenterol 2003; 98: 596-9.
48. Dupont HL. Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther 2014; 39: 1033-42.
49. Lomax AR, Calder PC. Prebiotics, immune function, infection and inflammation: a review of the evidence. Br J Nutr 2009; 101: 633-58.
50. Almansa C, Agrawal A, Houghton LA. Intestinal microbiota, pathophysiology and translation to probiotic use in patients with irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2012; 6: 383-98.
51. Brenner DM, Chey WD. Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. Rev Gastroenterol Disord. 2009; 9: 7-15.
52. Hungin AP, Mulligan C, Pot B, Whorwell P, Agreus L, Fracasso P, Lionis C, Mendive J et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide. Aliment Pharmacol Ther 2013; 38: 864-86.
53. Vazquez-Roque MI, Camilleri M, Smyrk T, Murray JA, Marietta E, O'Neill J, Carlson P, Lamsam J et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 2013; 144: 903-11 e903.
54. Nasser Y, Boeckxstaens GE, Wouters MM, Schemann M, Vanner S. Using human intestinal biopsies to study the pathogenesis of irritable bowel syndrome. Neurogastroenterol Motil 2014; 26: 455-69.
55. Valdez-Morales EE, Overington J, Guerrero-Alba R, Ochoa-Cortes F, Ibeakanma CO, Spreadbury I, Bunnett NW, Beyak M et al. Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients: a role for PAR2. Am J Gastroenterol 2013; 108: 1634-43.
56. Hughes PA, Harrington AM, Castro J, Liebregts T, Adam B, Grasby DJ, Isaacs NJ, Maldeniya L et al. Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes. Gut 2013; 62: 1456-65.
57. Bajor A, Tornblom H, Rudling M, Ung KA, Simren M. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut 2015; 64: 84-92.
58. Walters JR. Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol 2014; 11: 426-34.
59. Gracie DJ, Kane JS, Mumtaz S, Scarsbrook AF, Chowdhury FU, Ford AC. Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. Neurogastroenterol Motil 2012; 24: 983-e538.
60. Duboc H, Rainteau D, Rajca S, Humbert L, Farabos D, Maubert M, Grondin V, Jouet P et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012; 24: 513-20, e246-517.
61. Shin A, Camilleri M, Vijayvargiya P, Busciglio I, Burton D, Ryks M, Rhoten D, Lueke A et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013; 11: 1270-5 e1271.
62. Camilleri M, Vazquez-Roque MI, Burton D, Ford T, McKinzie S, Zinsmeister AR, Druzgala P. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007; 19: 30-8.
63. Schmulson MJ. Brain-gut interaction in irritable bowel syndrome: new findings of a multicomponent disease model. Isr Med Assoc J. 2001; 3: 104-10.
64. Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 2011; 12: 453-66.
65. Mayer EA, Collins SM. Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 2002; 122: 2032-48.
66. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107: 271-93.
67. Mayer EA, Naliboff BD, Chang L. Basic pathophysiologic mechanisms in irritable bowel syndrome. Dig Dis 2001; 19: 212-8.
68. Price DD, Craggs JG, Zhou Q, Verne GN, Perlstein WM, Robinson ME. Widespread hyperalgesia in irritable bowel syndrome is dynamically maintained by tonic visceral impulse input and placebo/nocebo factors: evidence from human psychophysics, animal models, and neuroimaging. NeuroImage 2009; 47: 995-1001.
69. Price DD, Zhou Q, Moshiree B, Robinson ME, Verne GN. Peripheral and central contributions to hyperalgesia in irritable bowel syndrome. J Pain. 2006; 7: 529-35.
70. Ohman L, Simren M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis 2007; 39: 201-15.
71. Sheehan J, Gaman A, Vangel M, Kuo B. Pooled analysis of brain activity in irritable bowel syndrome and controls during rectal balloon distension. Neurogastroenterol Motil 2011; 23: 336-46 e158.
72. Manabe N, Tanaka T, Hata J, Kusunoki H, Haruma K. Pathophysiology underlying irritable bowel syndrome - from the viewpoint of dysfunction of autonomic nervous system activity. J Smooth Muscle Res 2009; 45: 15-23.
73. Syme P. Are cardiac syndrome X, irritable bowel syndrome and reflex sympathetic dystrophy examples of lateral medullary ischaemic syndromes? Med Hypotheses 2005; 65: 145-8.
74. Miller SM. When is a little information a dangerous thing? Coping with stressful life events by monitoring vs blunting. In: Levine S, Ursin H, eds. Coping and Health. New York, NY: Plenum Press, 1980: 145-69.
75. Lembo T, Naliboff BD, Matin K, Munakata J, Parker RA, Gracely RH, Mayer EA. Irritable bowel syndrome patients show altered sensitivity to exogenous opioids. Pain 2000; 87: 137-47.
76. Chang L, Mayer EA, Labus JS, Schmulson M, Lee OY, Olivas TI, Stains J, Naliboff BD. Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. Am J Physiol Regul Integr Comp Physiol 2006; 291: R277-84.
77. Mayer EA, Naliboff B, Lee O, Munakata J, Chang L. Review article: gender-related differences in functional gastrointestinal disorders. Aliment Pharmacol Ther 1999; 13(Suppl. 2): 65-9.
78. Zar S, Benson MJ, Kumar D. Rectal afferent hypersensitivity and compliance in irritable bowel syndrome: differences between diarrhoea-predominant and constipation-predominant subgroups. Eur J Gastroenterol Hepatol 2006; 18: 151-8.
79. Harraf F, Schmulson M, Saba L, Niazi N, Fass R, Munakata J, Diehl D, Mertz H et al. Subtypes of constipation predominant irritable bowel syndrome based on rectal perception. Gut 1998; 43: 388-94.
80. Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008; 57: 923-9.
81. van Wanrooij SJ, Wouters MM, Van Oudenhove L, Vanbrabant W, Mondelaers S, Kollmann P, Kreutz F, Schemann M et al. Sensitivity testing in irritable bowel syndrome with rectal capsaicin stimulations: role of TRPV1 upregulation and sensitization in visceral hypersensitivity? Am J Gastroenterol 2014; 109: 99-109.
82. Castro J, Harrington AM, Hughes PA, Martin CM, Ge P, Shea CM, Jin H, Jacobson S et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3', 5'-monophosphate. Gastroenterology 2013; 145: 1334-46, e1-11.
83. Ellingson BM, Mayer E, Harris RJ, Ashe-McNally C, Naliboff BD, Labus JS, Tillisch K. Diffusion tensor imaging detects microstructural reorganization in the brain associated with chronic irritable bowel syndrome. Pain 2013; 154: 1528-41.
84. Letzen JE, Craggs JG, Perlstein WM, Price DD, Robinson ME. Functional connectivity of the default mode network and its association with pain networks in irritable bowel patients assessed via lidocaine treatment. J Pain. 2013; 14: 1077-87.
85. Bonaz B, Baciu M, Papillon E, Bost R, Gueddah N, Le Bas JF, Fournet J, Segebarth C. Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study. Am J Gastroenterol 2002; 97: 654-61.
86. Hall GB, Kamath MV, Collins S, Ganguli S, Spaziani R, Miranda KL, Bayati A, Bienenstock J. Heightened central affective response to visceral sensations of pain and discomfort in IBS. Neurogastroenterol Motil 2010; 22: 276-e80.
87. Labus JS, Gupta A, Coveleskie K, Tillisch K, Kilpatrick L, Jarcho J, Feier N, Bueller J et al. Sex differences in emotion-related cognitive processes in irritable bowel syndrome and healthy control subjects. Pain 2013; 154: 2088-99.
88. Seminowicz DA, Labus JS, Bueller JA, Tillisch K, Naliboff BD, Bushnell MC, Mayer EA. Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology 2010; 139: 48-57 e42.
89. Elsenbruch S, Schmid J, Kullmann JS, Kattoor J, Theysohn N, Forsting M, Kotsis V. Visceral sensitivity correlates with decreased regional gray matter volume in healthy volunteers: a voxel-based morphometry study. Pain 2014; 155: 244-9.
90. Hunt RH. Evolving concepts in the pathophysiology of functional gastrointestinal disorder. J Clin Gastroenterol 2002; 35: S2-6.
91. van Tilburg MA, Palsson OS, Whitehead WE. Which psychological factors exacerbate irritable bowel syndrome? Development of a comprehensive model. J Psychosom Res 2013; 74: 486-92.
92. Lackner J, Jaccard J, Baum C, Smith A, Krasner S, Katz L, Firth R, Raby T et al. Patient-reported outcomes for irritable bowel syndrome are associated with patients' severity ratings of gastrointestinal symptoms and psychological factors. Clin Gastroenterol Hepatol 2011; 9: 957-64 e951.
93. Lackner JM, Gudleski GD, Thakur ER, Stewart TJ, Iacobucci GJ, Spiegel BM. The impact of physical complaints, social environment, and psychological functioning on IBS patients' health perceptions: looking beyond GI symptom severity. Am J Gastroenterol 2014; 109: 224-33.
94. Dorn SD, Palsson OS, Thiwan SI, Kanazawa M, Clark WC, van Tilburg MA, Drossman DA, Scarlett Y et al. Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007; 56: 1202-9.
95. Labus JS, Hubbard CS, Bueller J, Ebrat B, Tillisch K, Chen M, Stains J, Dukes GE et al. Impaired emotional learning and involvement of the corticotropin-releasing factor signaling system in patients with irritable bowel syndrome. Gastroenterology 2013; 145: 1253-61, e1251-1253.
96. Spiegel B, Strickland A, Naliboff BD, Mayer EA, Chang L. Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol 2008; 103: 2536-43.
97. Labus J, Gupta A, Gill HK, Posserud I, Mayer M, Raeen H, Bolus R, Simren M et al. Randomised clinical trial: symptoms of the irritable bowel syndrome are improved by a psycho-education group intervention. Aliment Pharmacol Ther 2013; 37: 304-15.
98. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-31.
99. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-98.
100. Whitehead WE. Twin studies used to prove that the comorbidity of major depressive disorder with IBS is NOT influenced by heredity. Am J Gastroenterol 2007; 102: 2230-1.
101. Toner BB, Garfinkel PE, Jeejeebhoy KN. Psychological factors in irritable bowel syndrome. Can J Psychiatry 1990; 35: 158-61.
102. Bradford K, Shih W, Videlock EJ, Presson AP, Naliboff BD, Mayer EA, Chang L. Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol 2012; 10: 385-90, e381-383.
103. Salmon P, Skaife K, Rhodes J. Abuse, dissociation, and somatization in irritable bowel syndrome: towards an explanatory model. J Behav Med 2003; 26: 1-18.
104. Walker LS, Williams SE, Smith CA, Garber J, Van Slyke DA, Lipani TA. Parent attention versus distraction: impact on symptom complaints by children with and without chronic functional abdominal pain. Pain 2006; 122: 43-52.
105. Gerson CD, Gerson MJ. A cross-cultural perspective on irritable bowel syndrome. Mt Sinai J Med 2010; 77: 707-12.
106. Miranda A. Early life stress and pain: an important link to functional bowel disorders. Pediatr Ann 2009; 38: 279-82.
107. O'Mahony SM, Hyland NP, Dinan TG, Cryan JF. Maternal separation as a model of brain-gut axis dysfunction. Psychopharmacology 2011; 214: 71-88.
108. Gareau MG, Silva MA, Perdue MH. Pathophysiological mechanisms of stress-induced intestinal damage. Curr Mol Med 2008; 8: 274-81.
109. Larauche M, Mulak A, Tache Y. Stress and visceral pain: from animal models to clinical therapies. Exp Neurol 2012; 233: 49-67.
110. Tache Y, Kiank C, Stengel A. A role for corticotropin-releasing factor in functional gastrointestinal disorders. Curr Gastroenterol Rep 2009; 11: 270-7.
111. Khasar SG, Burkham J, Dina OA, Brown AS, Bogen O, Alessandri-Haber N, Green PG, Reichling DB et al. Stress induces a switch of intracellular signaling in sensory neurons in a model of generalized pain. J Neurosci 2008; 28: 5721-30.
112. Barreau F, Ferrier L, Fioramonti J, Bueno L. New insights in the etiology and pathophysiology of irritable bowel syndrome: contribution of neonatal stress models. Pediatr Res 2007; 62: 240-5.
113. Sperber AD, Dekel R. Irritable bowel syndrome and co-morbid gastrointestinal and extra-gastrointestinal functional syndromes. J Neurogastroenterol Motil. 2010; 16: 113-9.
114. Henningsen P, Zipfel S, Herzog W. Management of functional somatic syndromes. Lancet 2007; 369: 946-55.
115. Kim SE, Chang L. Overlap between functional GI disorders and other functional syndromes: what are the underlying mechanisms? Neurogastroenterol Motil 2012; 24: 895-913.
116. Cady RK, Farmer K, Dexter JK, Hall J. The bowel and migraine: update on celiac disease and irritable bowel syndrome. Curr Pain Headache Rep 2012; 16: 278-86.
117. Locke GR 3rd, Zinsmeister AR, Fett SL, Melton LJ 3rd, Talley NJ. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil 2005; 17: 29-34.
118. Smith HS, Barkin RL. Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy. Am J Ther 2010; 17: 418-39.
119. Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001; 134: 868-81.
120. Bullones Rodriguez MA, Afari N, Buchwald DS. Evidence for overlap between urological and nonurological unexplained clinical conditions. J Urol 2013; 189: S66-74.
121. Mayer EA, Fass R, Fullerton S. Intestinal and extraintestinal symptoms in functional gastrointestinal disorders. Eur J Surg Suppl 1998; (583): 29-31.
122. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011; 152: S2-15.
123. Kindler LL, Bennett RM, Jones KD. Central sensitivity syndromes: mounting pathophysiologic evidence to link fibromyalgia with other common chronic pain disorders. Pain Manag Nurs. 2011; 12: 15-24.
124. Mease PJ. Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors. Am J Med 2009; 122: S44-55.
125. Staud R. Abnormal endogenous pain modulation is a shared characteristic of many chronic pain conditions. Expert Rev Neurother 2012; 12: 577-85.
126. Abbi B, Natelson BH. Is chronic fatigue syndrome the same illness as fibromyalgia: evaluating the 'single syndrome' hypothesis. QJM 2013; 106: 3-9.
127. Aggarwal VR, McBeth J, Zakrzewska JM, Lunt M, Macfarlane GJ. The epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors? Int J Epidemiol 2006; 35: 468-76.
128. Fikree A, Grahame R, Aktar R, Farmer AD, Hakim AJ, Morris JK, Knowles CH, Aziz Q. A prospective evaluation of undiagnosed joint hypermobility syndrome in patients with gastrointestinal symptoms. Clin Gastroenterol Hepatol 2014; 12: 1680-7.
129. National Institute for Health and Care Excellence. Irritable Bowel Syndrome in Adults. Diagnosis and Management of Irritable Bowel Syndrome in Primary Care. London: NICE, 2008.
130. van Ravenzwaaij J, Olde Hartman T, van Ravesteijn H, Eveleigh R, van Rijswijk E, Lucassen P. Explanatory models of medically unexplained symptoms: a qualitative analysis of the literature. Ment Health Fam Med. 2010; 7: 223-31.